Study of fruquintinib, tislelizumab, and radiation for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs (fruquintinib and tislelizumab) followed by radiation therapy for people with advanced esophageal squamous cell carcinoma. The goal is to see if this approach can help shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of esophageal squamous cell carcinoma that has not spread to distant organs.
- Your tumor must be measurable on a CT or MRI scan (at least 1 cm in size).
- You must not have received radiation to the chest or immunotherapy before.
- Your blood counts, liver, kidney, heart, and lung function must be within certain limits.
- You must be willing to stop other cancer treatments for at least 4 weeks before starting the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment for advanced or metastatic esophageal cancer that has not responded to previous chemotherapy. It aims to see if this treatment can help slow down the cancer or shrink tumors.
This trial tests a short course of radiation combined with two drugs (raltitrexed and tislelizumab) for people with esophageal cancer that has returned after standard treatment. The goal is to see if these combinations can shrink tumors and improve survival.
This study tests a new combination of two drugs (fruquintinib and sintilimab) plus focused radiation for people with advanced stomach or gastroesophageal junction cancer that has progressed after earlier treatments. The goal is to see if this approach can help control the cancer.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and radiation, followed by surgery, for people with advanced esophageal cancer that cannot be removed right away. It aims to see if this approach can help shrink the tumor enough to allow surgery.
This trial tests whether combining tislelizumab (an immunotherapy drug) with chemotherapy can shrink advanced esophageal cancer before surgery. The goal is to help patients whose tumors are too large or invasive to operate on initially.
This trial tests whether giving tislelizumab (an immunotherapy) along with chemotherapy before and after surgery can help people with a type of esophageal cancer called squamous cell carcinoma. The goal is to see if this combination improves outcomes for patients whose cancer is in the chest and can be removed with surgery.
Hear when a new Esophageal Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.